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ABSTRACT 
Objectives: To synthesize, characterize and evaluate antimicrobial properties of some benzenesulfonamide based bipyrazole. 
Methods: The benzenesulfonamide based bipyrazole 1a-d & 2a-f have been synthesized by the reaction between 1-[1-aryl / (benzothiazol-2-yl)-5-
hydroxy-3-methylpyrazol-4-yl]butane-1,3-diones 5 and 2-hydrazinobenzothiazoles or Aryl hydrazines 3. The structures of these compounds have 
been characterized from the rigorous analysis of their IR, 1H-NMR, HRMS and elemental analysis. These compounds were screened for their anti-
microbial activity.  
Results: The results revealed that compounds 1a, 2b and 2f exhibited good antibacterial activity and 1b, 1c, 2a, and 2d showed moderate 
antibacterial activity as compared with standard drug Ofloxacin. 
Conclusion: This study provides the simple method for the synthesis of new benzenzenesulfonamide based bipyrazoles which plays important role 
in numerous bioactive compounds. 
Keywords: Bipyrazole, Butane-1,3-diones, 2-Hydrazinobenzothiazoles, Arylhydrazines, Benzenesulfonamide, Anti-microbial. 
 
INTRODUCTION 
Benzenesulfonamide functional group plays important role in 
numerous bioactive compounds [1, 2]. The interest in this functional 
group has widened since the discovery of two Cyclooxygenase (COX) 
isoforms in the early 1990s [3-5]. Pyrazole derivatives have a long 
history of application in the agrochemical and the pharmaceutical 
industry [6, 7] as herbicides, insecticides [8, 9] and as part of 
biologically active pharmaceuticals [10, 11]. Celebrex [10], a 
currently marketed selective COX-2 inhibitor, is a pyrazole 
derivative incorporated with benzenesulfonamide functional group. 
In place of the central pyrazole ring a large no of heterocycles [1] 
such as thiophene, furanone, pyridine, thiazole, triazole and oxazole 
have been reported to possess good COX-2 inhibitory activity. There 
are only few examples of replacement of the aryl substituents with 
some heterocycles [10] have been reported to possess excellent 
potency and selectivity. Several COX-2 inhibitors containing sulfone 
/ sulfonamide moiety have been withdrawn from the market or 
clinical development. In fact celecoxib is still in the market but being 
prescribed cautiously. Inhibition of carbonic anhydrase is another 
problem of sulfonamide class of compounds. 
In view of above facts and observations, we have therefore, 
synthesized two series of compounds, namely, 1-[(4-
aminosufonyl)phenyl]-3-methyl-5-[1-aryl/heterocyclyl-5-hydroxy-
3-methylpyrazol-4-yl]pyrazoles (1a-d) and 1-aryl/heterocyclyl-3-
methyl-5-[1-(4-aminosulfonyl)phenyl-5-hydroxy-3-methylpyrazol-
4-yl]pyrazoles (2a-f), in which the 5-aryl substituent of the lead class 
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MATERIALS AND METHODS 
All the chemicals required were purchased from the local suppliers 
and were purified by established methods. The melting points were 
recorded by open capillary method and are uncorrected. The purity 
and homogeneity of the synthesized compounds were routinely 
ascertained by the thin layer chromatography, performed on plates 
coated with silica gel-G. All compounds were isolated and purified by 
thin layer chromatography and column chromatography 
respectively. The visualization was done using iodine vapours and U. 
V. light chamber.  
The 1H NMR spectra were recorded on a Bruker 300 MHz 
instrument using CDCl3 or DMSO-d6 solvents and TMS (Tetra methyl 
silane) as internal standard. Chemical shifts (δ) are reported in ppm 
and coupling constants J are given in Hz. IR spectra were recorded 
using KBr disks with a Buck Scientific IR M-500 infrared 
spectrometer. High-resolution mass spectra were measured on a 
Kratos MS-50 mass spectrometer. 
Experimental 
Synthesis of 4-[5-(1-substituted-5-hydroxy-3-methylpyrazol-4-
yl]-3-methylpyrazol-1-yl]benzenesulfonamides (1) and 4-[5-
hydroxy-3-methyl-4-(1-substituted-3-methylpyrazol-5-
yl)pyrazol-1-yl]benzenesulfonamides (2)  
Phenylhydrazone of DHAA (4a) 
Dehydroacetic acid (DHAA) (3.36 g, 0.02 mol) was dissolved in 
ethanol (50 ml) by warming and phenylhydrazine (2 ml, 0.02 mol) 
was added in it while shaking. The contents were stirred for 10 min. 
and allowed to stand at room temperature for 2 hrs. The yellow solid 
so obtained was filtered, crystallized from acetonitrile, mp 211ο (mp 
212ο [12]) yield 81%. 
Other hydrazones of DHAA (4b-4d) were prepared similarly by 
treating DHAA with corresponding hydrazines. 
4-Chlorophenylhydrazone of DHAA (4b) 
mp 250ο (mp 252ο[12]), yield 66%. 
6-Chlorobenzothiazol-2-ylhydrazone of DHAA (4c) 
mp 185-186ο (mp 186ο[13]), yield 60%. 
4-Sulfamoylphenylhydrazone of DHAA (4d) 
mp 232-234ο, yield 70%, IR (KBr) cm-1: 3309-3081 (br, O-H & N-H 
stretch), 1716 (s, C=O stretch), 1317 & 1149 (s, SO2 stretch), 1H NMR 
(CDCl3, 300MHz): δ 2.28 (s, 3H, pyrone C6-CH3), 2.64 (s, 3H, CH3-C=N-
), 6.01 (s, 1H, pyrone C5-H),7.10-7.13 (d, 2H, J=8.8Hz, C3′-H & C5′-H), 
7.71-7.68 (d, 2H, J=8.8Hz, C2′-H & C6′-H) 
1-[5-Hydroxy-3-methyl-1-phenylpyrazol-4-yl]butane-1,3-dione 
(5a) 
Phenylhydrazone of DHAA (0.01 mol) was dissolved in glacial acetic 
acid (30 ml) and the solution refluxed for 1.5 hrs. The solvent was 
distilled off at reduced pressure and the residue was crystallized 
from acetonitrile, mp 101ο (mp 101-102ο[12]), yield 66%. 




mp 150ο(mp 151ο[12]), yield 67%. 
1-[1-(6-Chlorobenzothiazol-2-yl)-5-hydroxy-3-methylpyrazol-
4-yl]butane-1,3-dione (5c) 
mp 216ο (mp 217ο[13]), yield 63%. 
1-[1-(4-Sulfamoylphenyl)-5-hydroxy-3-methylpyrazol-4-yl]-
butane-1,3-dione (5d) 
mp 195-197ο, yield 55%, IR (KBr) cm-1: 3294 & 3174 (br, O-H & N-H 
stretch), 1666 (s, C=O stretch), 1324 & 1159 (s, SO2 stretch). 1H NMR 
(CDCl3, 300MHz): δ 2.12 (s, 3H, -CO-CH3), 2.51 (s, 3H, pyrazolone C3-CH3), 
6.65 (s, 2H, -CO-CH2-CO-), 7.90-8.01 (m, 4H, C2′-H, C3′-H, C5′-H & C6′-H). 
4-[5-(5-hydroxy-3-methyl-1-phenylpyrazol-4-yl)-3-
methylpyrazol-1-yl]benzenesulfonamide (1a)  
To an ethanolic solution of 1-[5-hydroxy-3-methyl-1-phenylpyrazol-
4-yl]butane-1,3-dione (5 mmol) was added 4-sulfamoyl 
phenylhydrazine (5 mmol) and the contents having a few drops of 
concentrated HCl were refluxed for 3 hrs. The reaction mixture was 
concentrated and cooled at room temperature. A crystalline solid 
was obtained, filtered and dried. mp 152-154ο, yield 51%, IR (KBr) 
cm-1: 3570 (m, O-H stretch), 3394 & 3315 (m, N-H stretch), 1624 (s, 
N-H bend), 1335 & 1162 (s, SO2 stretch). 
1H NMR (CDCl3/DMSO-d6): 
δ1.95 (s, 3H, pyrazolone C3′-CH3), 2.36 (s, 3H, pyrazole C3-CH3), 6.29 
(s, 1H, pyrazole C4-H), 7.22-7.27 (t, 1H, J=7.6Hz, C4′″-H), 7.38-7.43 (t, 
2H, J=7.6Hz, C3′″-H & C5′″-H), 7.53-7.56 (d, 2H, J=8.6Hz, C2″-H & C6″-H), 
7.67-7.70 (d, 2H, J=7.6Hz, C2′″-H & C6′″-H), 7.85-7.88 (d, 2H, J=8.6Hz, 
C3″-H & C5″-H); MS: m/z 409.1212 (M
+, 35.5%); Anal. Found: C, 58.45; 
H, 4.80; N, 17.51%. Calcd. for C20H19N5O3S: C, 58.67; H, 4.68; N, 
17.10%. 
4-[5-{1-(4-chlorophenyl)-5-hydroxy-3-methylpyrazol-4-yl}-3-
methylpyrazol-1-yl]benzenesulfonamide (1b)  
mp 187-189ο, yield 53%, IR (KBr) cm-1:3360 (m, O-H stretch), 3230 
& 3105 (m, N-H stretch), 1642 (s, N-H bend), 1336 & 1163 (s, SO2 
stretch); 1H NMR (CDCl3/DMSO-d6): δ2.01 (s, 3H, pyrazolone C3′-
CH3), 2.43 (s, 3H, pyrazole C3-CH3), 6.36 (s, 1H, pyrazole C4-H), 7.38-
7.41 (d, 2H, J=8.5Hz, C3′″-H & C5′″-H), 7.56-7.59 (d, 2H, J=8.2Hz, C2″-H 
& C6″-H), 7.67-7.70 (d, 2H, J=8.5Hz, C2′″-H & C6′″-H), 7.91-7.94 (d, 2H, 
J=8.2Hz, C3″-H & C5″-H); MS: m/z 445.0834 / 443.0826 (M
++2 / M+, 
13.4%); Anal. Found: C, 58.37; H, 4.48; N, 15.51%. Calcd. for 
C20H18ClN5O3S: C, 54.11; H, 4.09; N, 15.78%. 
4-[5-{1-(6-chlorobenzothiazol-2-yl)-5-hydroxy-3-methyl 
pyrazol-4-yl}-3-methylpyrazol-1-yl]benzenesulfonamide (1c)  
mp 276-277ο, yield 52%, IR (KBr) cm-1: 3355-3058 (br, O-H & N-H 
stretch), 1648 (s, N-H bend), 1338 & 1161 (s, SO2 stretch); 
1H NMR 
(CDCl3/DMSO-d6): δ2.00 (s, 3H, pyrazolone C3′-CH3), 2.37 (s, 3H, 
pyrazole C3-CH3), 6.33 (s, 1H, pyrazole C4-H), 7.40-7.44 (dd, 1H, J=8.5 
& 1.9Hz, C5′″-H), 7.60-7.63 (d, 2H, J=8.6Hz, C2″-H & C6″-H), 7.72-7.75 
(d, 1H, J=8.5Hz, C4′″-H), 7.85-7.86 (d, 1H, J=1.9Hz, C7′″-H), 7.89-7.92 
(d, 2H, J=8.6Hz, C3″-H & C5″-H); MS: m/z 502.0460 / 500.0491 (M
++2 
/ M+, 100%); Anal. Found: C, 50.67; H, 3.68; N, 16.93%. Calcd. for 
C20H17ClN6O3S2: C, 50.35; H, 3.42; N, 16.78%. 
4-[5-hydroxy-3-methyl-4-{3-methyl-1-(4-
sulfamoylphenyl)pyrazol-5-yl}pyrazol-1-
yl]benzenesulfonamide (1d)  
mp 284ο(decomp), yield 54%, IR (KBr) cm-1: 3596 (m, O-H stretch), 3374 
& 3272 (m, N-H stretch), 1625 (s, N-H bend), 1330 & 1160 (s, SO2 
stretch); 1H NMR (CDCl3/DMSO-d6): δ1.95 (s, 3H, pyrazolone C3′-CH3), 
2.38 (s, 3H, pyrazole C3-CH3), 6.30 (s, 1H, pyrazole C4-H), 7.57-7.60 (d, 2H, 
J=8.1Hz, C2″-H & C6″-H), 7.86-7.93 (m 6H, C3″-H, C5″-H, C2′″-H, C3′″-H, C5′″-H & 
C6′″-H); MS: m/z 488.0941 (M
+, 47.9%); Anal. Found: C, 49.52; H, 4.38; N, 
16.93%. Calcd. for C20H20N6O5S2: C, 49.17; H, 4.13; N, 17.20%. 
4-[5-hydroxy-3-methyl-4-(3-methyl-1-phenylpyrazol-5-
yl)pyrazol-1-yl]benzenesulfonamide (2a)  
mp 199-200ο, yield 42%, IR (KBr) cm-1: 3431 (m, O-H stretch), 3294 
& 3216 (m, N-H stretch), 1650 (s, N-H bend), 1332 & 1170 (s, SO2 
stretch); 1H NMR (CDCl3/DMSO-d6): δ 1.91 (s, 3H, pyrazolone C3′-
CH3), 2.48 (s, 3H, pyrazole C3-CH3), 6.46 (s, 1H, pyrazole C4-H), 6.96-
7.49 (m, 8H, C2″-H, C3″-H, C4″-H, C5″-H, C6″-H, pyrazole C5-OH & C4′″-
SO2NH2), 7.94 (bs, 4H, C2′″-H, C3′″-H, C5′″-H & C6′″-H); MS: m/z 
409.1204 (M+, 37.1%); Anal. Found: C, 58.40; H, 4.78; N, 17.51%. 
Calcd. for C20H19N5O3S: C, 58.67; H, 4.68; N, 17.10%. 
4-[4-{1-(4-chlorophenyl)-3-methylpyrazol-5-yl}-5-hydroxy-3-
methylpyrazol-1-yl]benzenesulfonamide (2b)  
mp 290ο, yield 53%, IR (KBr) cm-1: 3410 (m, O-H stretch), 3345 & 
3270 (m, N-H stretch), 1553 (s, N-H bend), 1336 & 1163 (s, SO2 
Singh et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 10, 345-351 
 
stretch); 1H NMR (CDCl3/DMSO-d6): δ 1.99 (s, 3H, pyrazolone C3′-
CH3), 2.37 (s, 3H, pyrazole C3-CH3), 6.89 (bs, 2H, pyrazole C4-H & 
pyrazolone C5′-OH), 7.39-7.42 (d, 2H, J=8.8Hz, C3″-H & C5″-H), 7.48-
7.51 (d, 2H, J=8.8Hz, C2″-H & C6″-H), 7.93-7.96 (d, 2H, J=8.7Hz, C2′″-H 
& C6′″-H), 8.11-8.14 (d, 2H, J=8.7Hz, C3′″-H & C5′″-H); MS: m/z 
445.0781 / 443.0827 (M++2 / M+, 32.0%); Anal. Found: C, 58.29; H, 
4.28; N, 16.93%. Calcd. for C20H19N5O3S: C, 58.67; H, 4.68; N, 17.11%. 
4-[4-{1-(2,4-dichlorophenyl)-3-methylpyrazol-5-yl}-5-hydroxy-
3-methylpyrazol-1-yl]benzenesulfonamide (2c)  
mp 158-160ο, yield 59%, IR (KBr) cm-1: 3510 (m, O-H stretch), 3214 
& 3136 (m, N-H stretch), 1587 (s, N-H bend), 1337 & 1185 (s, SO2 
stretch); 1H NMR (CDCl3/DMSO-d6): δ 2.04 (s, 3H, pyrazolone C3′-
CH3), 2.37 (s, 3H, pyrazole C3-CH3), 6.26 (s, 1H, pyrazole C4-H), 7.28-
7.32 (dd, 1H, J=8.6 & 2.3Hz, C5″-H), 7.43-7.44 (d, 1H, J=2.3Hz, C3″-H), 
7.52-7.55 (d, 1H, J=8.6Hz, C6″-H), 7.83-7.86 (d, 2H, J=8.8Hz, C2′″-H & 
C6′″-H), 7.89-7.92 (d, 2H, J=8.8Hz, C3′″-H & C5′″-H); MS: m/z 481.0631 
/ 479.0542 / 477.0431 (M++4 / M++2 / M+, 52.3%); Anal. Found: C, 
50.11; H, 4.01; N, 14.51%. Calcd. for C20H17Cl2N5O3S: C, 50.22; H, 
3.58; N, 14.64%. 
4-[5-hydroxy-3-methyl-4-{3-methyl-1-(6-methylbenzothiazol-2-
yl)pyrazol-5-yl}pyrazol-1-yl]benzenesulfonamide (2d)  
mp 298ο, yield 54%, IR (KBr) cm-1: 3499 (m, O-H stretch), 3110 & 
3059 (m, N-H stretch), 1633 (s, N-H bend), 1331 & 1163 (s, SO2 
stretch); 1H NMR (CDCl3/DMSO-d6): δ 2.27 (s, 3H, pyrazolone C3′-
CH3), 2.41 (s, 3H, pyrazole C3-CH3), 2.48 (s, 3H, C6″-CH3), 6.34 (s, 1H, 
pyrazole C4-H), 6.82 (bs, 2H, C4′″-SO2NH2), 7.27-7.30 (dd, 1H, J=8.3 & 
1.1Hz, C5″-H), 7.64 (d, 1H, J=1.1Hz, C7″-H), 7.66-7.68 (d, 1H, J=8.3Hz, 
C4″-H), 7.99-8.02 (d, 2H, J=8.8Hz, C2′″-H & C6′″-H), 8.07-8.10 (d, 2H, 
J=8.8Hz, C3′″-H & C5′″-H); MS: m/z 480.1041 (M
+, 100%); Anal. Found: 
C, 54.58; H, 4.03; N, 17.51%. Calcd. for C22H20N6O3S: C, 54.98; H, 4.19; 
N, 17.49%. 
4-[4-{1-(6-chlorobenzothiazol-2-yl)-3-methylpyrazol-5-yl}-5-
hydroxy-3-methylpyrazol-1-yl]benzenesulfonamide (2e)  
mp 300ο(decomp), yield 65%, IR (KBr) cm-1: 3511-3077 (br, O-H & N-H 
stretch), 1630 (s, N-H bend), 1332 & 1162 (s, SO2 stretch); 
1H NMR 
(CDCl3/DMSO-d6): δ 2.23 (s, 3H, pyrazolone C3′-CH3), 2.41 (s, 3H, pyrazole 
C3-CH3), 6.35 (s, 1H, pyrazole C4-H), 6.82 (bs, 2H, C4′″-SO2NH2), 7.38-7.41 
(dd, 1H, J=8.7 & 1.8Hz, C5″-H), 7.69-7.72 (d, 1H, J=8.7Hz, C4″-H), 7.82-7.83 
(d, 1H, J=1.8Hz, C7″-H), 7.97-8.00 (d, 2H, J=8.9Hz, C2′″-H & C6′″-H), 8.04-
8.07 (d, 2H, J=8.9Hz, C3′″-H & C5′″-H); MS: m/z 502.0460 / 500.0500 
(M++2 / M+, 100%); Anal. Found: C, 50.05; H, 3.61; N, 16.48%. Calcd. for 
C22H17ClN6O3S2: C, 50.35; H, 3.42; N, 16.78%. 
4-[5-hydroxy-4-{1-(6-methoxybenzothiazol-2-yl)-3-methyl 
pyrazol-5-yl}-3-methylpyrazol-1-yl]benzenesulfonamide (2f)  
mp 304ο, yield 73%, IR (KBr) cm-1: 3500-3083 (br, O-H & N-H stretch), 
1627 (s, N-H bend), 1334 & 1165 (s, SO2 stretch). 
1H NMR (CDCl3/DMSO-
d6): δ 2.19 (s, 3H, pyrazolone C3′-CH3), 2.39 (s, 3H, pyrazole C3-CH3), 3.86 
(s, 3H, C6″-OCH3), 6.36 (s, 1H, pyrazole C4-H), 6.99-7.03 (dd, 1H, J=8.9 & 
2.5Hz, C5″-H), 7.18 (bs, 1H, pyrazolone C5′-OH), 7.38-7.39 (d, 1H, J=2.5Hz, 
C7″-H), 7.62-7.65 (d, 1H, J=8.9Hz, C4″-H), 7.94-7.97 (d, 2H, J=8.8Hz, C2′″-H & 
C6′″-H), 8.01-8.04 (d, 2H, J=8.8Hz, C3′″-H & C5′″-H); MS: m/z 496.0979 (M
+, 
100%); Anal. Found: C, 53.35; H, 3.92; N, 16.78%. Calcd. for C22H20N6O4S2 
requires: C, 53.21; H, 4.06; N, 16.92%. 
Evaluation of antibacterial activity 
A Disc Diffusion Method (Kirby Bauer Method) was employed for the 
in vitro study of antibacterial activity against two gram positive 
bacteria namely Staphylococcus aureus and Bacillus subtilis and two 
gram negative bacteria namely Salmonella species and Pseudomonas 
species. Ofloxacin was used as standard drug.  
Approximately 4 to 5 well isolated colonies of the bacterial strain are 
inoculated into 5 ml of nutrient broth and incubated at 37°C. After 
standardization of bacterial suspension, sterile cotton swap was 
immerged in it and the swap was rotated several times, with firm 
pressure on the inside wall of the tube to remove excess fluid. 
Nutrient agar media plate was prepared with a depth of 4 mm 
(millimetre).  
Dried surface of nutrient agar plate was inoculated by streaking the 
swab 3 times over the entire agar surface. Antibacterial impregnated 
disc was placed on the surface of the agar using sterile forceps and 
disc was pressed gently to provide uniform contact. Compounds (1a-
1d and 2a-2f) were evaluated for antibacterial activity. 
RESULTS AND DISCUSSION 
Condensation of appropriate hydrazine and 1,3-diketone is one of 
the most widely used methods for the synthesis of pyrazoles. 
Mechanism of this apparently simple reaction still evolves a lot of 
interest in the scientific community as complications are 
encountered in the delineation of reaction pathways when a 
substituted hydrazine and an unsymmetrical 1,3-diketone react.  
The present study concerns the preparation of bipyrazoles 
incorporated with benzenesulfonamide functional group. The 
reaction of dehydroacetic acid (DHAA) with aryl / benzothiazol-2-yl 
hydrazines (3a-d) in ethanol resulted in the formation of 
hydrazones (4a-d) which on refluxing in acetic acid underwent a 
rearrangement involving a nitrogen nucleophilic attack at the C2-
lactone carbonyl with ring opening to yield 1-[1-aryl / 
(benzothiazol-2yl)-5-hydroxy-3-methylpyrazol-4-yl]-butane-1,3-
diones (5a-d) (Scheme 1). 
Various arylhydrazines [15] and 2-hydrazinobenzothiazoles [16] 
needed for the present study, were prepared according to the 
literature procedures. The bipyrazoles (1a-d) were prepared by the 
reaction between 1-[1-aryl / (benzothiazol-2yl)-5-hydroxy-3-
methylpyrazol-4-yl]-butane-1,3-diones (5a-d) and (4-





A plausible mechanism [14] for the formation of 1-[1-aryl / (benzothiazol-2yl)-5-hydroxy-3-methylpyrazol-4-yl]-butane-1,3-diones (5a-d) is 
outlined in Scheme 2. 
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Table 1: The physical data of substituted hydrazones (4a-d) and diketones (5a-d) 
Compound No. Structure Formula MW amp (oC) bYield % 
4a 
 
C14H14N2O3 258.27 211-212 (212) 81 
4b 
 
C14H13ClN2O3 292.72 250-252 (252) 66 
4c 
 
C15H12ClN3O3S 349.79 185-186 (186) 60 
4d 
 
C14H15N3O5S 337.35 232-234 70 
5a 
 
C14H14N2O3 258.27 100-101 (102) 66 
5b 
 
C14H13ClN2O3 292.72 150 (151) 67 
5c 
 
C15H12ClN3O3S 349.79 216 (217) 63 
5d 
 
C14H15N3O5S 337.35 195-197 55 
auncorrected melting points, bsynthesized yields 
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Formally, Dehydroacetic acid (DHAA) possesses four sites for 
nucleophilic attack [17]. In principle, the condensation of either of 
the two nitrogen atoms of the hydrazine can occur on the side chain 
carbonyl group of DHAA followed by acidic arrangement involving a 
nitrogen nucleophilic attack at the C2-lactone carbonyl with ring 
opening leads to the formation of two isomeric β-diketones which on 
reaction with (4-aminosulfonyl)phenylhydrazine can yield four 





However, the determination of β-diketone structure will simplify the 
problem of assigning one of the four isomeric (bipyrazolyl) 
benzenesulfonamides. Literature results [18] showed that the 
secondary nitrogen atom is less nucleophilic than primary nitrogen 
atom; the most probable route for this reaction seems to be that 
leading to the formation of β-diketone 5. The formation of β-
diketone 5 is also supported by the similar results obtained in the 
literature [12, 14]. Further NOE experiment study provided 
convincing evidence that the β-diketone in our case is 5 not isomer 
6. Therefore, possibility of formation of (bipyrazolyl)benzene 
sulfonamides 8 and 9 stand discarded. 
In the event, condensation of β-diketone 5a with (4-aminosulfonyl) 
phenylhydrazine in absolute ethanol containing few drops of conc. 
HCl resulted in the formation of hydrazone followed by cyclization 
through an intramolecular Friedel-Crafts reaction yielded only a 
single product as confirmed by thin layer chromatography (TLC) and 
the 1H NMR spectra. The structure of this product was assigned as 4-
[5-(5-hydroxy-3-methyl-1-phenylpyrazol-4-yl)-3-methylpyrazol-1-
yl]benzenesulfonamide (1a), based on a rigorous analysis of its 300 
MHz 1H NMR spectrum. The 300 MHz 1H NMR spectrum of 
compound 1a showed two three-proton singlets due to two methyl 
groups appearing at δ1.95 and δ2.36 in the aliphatic region. It has 
earlier been observed through the NOE experimental study that 
upfield signal is due to methyl group located on the pyrazolone 
moiety (C3'-CH3) while the downfield signal is due to methyl group 
located on the pyrazole moiety (C3-CH3) [19].  
The unexpected shielding of the 3-methyl protons of the pyrazolone 
moiety can be explained on the basis that the C3'-CH3 protons fall in 
the shielding zone of the phenyl ring. The signal of the C3-CH3 group 
at δ2.36 in DMSO-d6 is singlet which showed that there is no 
coupling between this methyl group and C4-H. This is the 
characteristics of a methyl group in position 3 of the pyrazole ring 
[20]. Had it been the isomeric 7a, the signal for the methyl group 
would show allylic coupling of 0.5-0.7 Hz with C4-H. These 
observations all support the structure 1a for the isolated product. 
Other compounds in this series 1b-1d were prepared following the 
procedure similar to that adopted for 1a by the reaction between β-
diketones 5 and (4-aminosulfonyl)phenyl hydrazine. Their 
elemental analyses as well as spectral data were consistent with the 
assigned structures of all the new compounds. 
After successful synthesis of compounds 1a-d, we focused our 
attention on the synthesis of regioisomeric compounds 2a-f in which 
the (4-aminosulfonyl)phenyl substituent is shifted to N-1 of 
pyrazolone moiety from the N-1 of the pyrazole ring. In a way it will 
amount to the shifting of the (4-aminosulfonyl)phenyl grouping 
from N-1 to the substituent at the 5-position of the pyrazole ring in 
the lead class 1,5-diarylpyrazoles. 1-Aryl/heterocyclyl-3-methyl-5-
[1-(4-aminosulfonyl) phenyl-5-hydroxy-3-methyl pyrazol-4-yl] 
pyrazoles (2a-f) were synthesized by the reaction of 1-[1-(4-
aminosulfonyl) phenyl-5-hydroxy-3-methylpyrazol-4-yl]-1,3-
butandione (5d) with various aryl/heterocyclyl hydrazines following a 
reaction sequence similar to as shown earlier in Scheme 3. 
 
Table 2: The physical data of bipyrazoles (1a-d) and (2a-f) 
Compound No. Structure Formula MW amp (oC) bYield % 
1a 
 
C20H19N5O3S 409.46 152-154 51 
1b 
 
C20H18ClN5O3S 443.91 187-189 53 
1c 
 
C21H17ClN6O3S2 500.98 276-277 52 
Singh et al. 




C20H20N6O5S2 488.54 284 (decomp) 54 
2a 
 
C20H19N5O3S 409.46 199-200 42 
2b 
 
C20H18ClN5O3S 443.91 290 53 
2c 
 
C20H17Cl2N5O3S 478.35 158-160 59 
2d 
 
C22H20N6O3S2 480.56 298 54 
2e 
 
C21H17ClN6O3S2 500.98 300(decomp) 65 
2f 
 
C22H20N6O4S2 496.56 304 73 
auncorrected melting points, bsynthesized yields 
 
Table 3: Antibacterial activity of synthesized compounds 









S. aureus % 
Inhibition 
B. subtilis % 
Inhibition 
1a 17.4±1.000 60.83 17.2±0.866 60.35 19.2±0.860 67.36 16.8±2.160 54.01 
1b 15.2±1.000 53.14 14.9±0.866 52.28 16.9±0.860 59.30 14.8±2.160 47.59 
1c 14.4±1.000 50.34 13.6±0.866 47.72 15.5±0.860 54.38 13.8±2.160 44.37 
1d 13.3±1.000 46.50 13.1±0.866 45.96 15.1±0.860 52.98 15.8±2.160 50.80 
2a 16.2±1.000 56.64 16.5±0.866 57.89 19.5±0.860 68.42 14.6±2.160 46.94 
2b 17.8±1.000 62.23 17.2±0.866 60.35 19.2±0.860 67.36 17.3±2.160 55.63 
2c 12.6±1.000 44.05 12.2±0.866 42.80 15.2±0.860 53.33 12.8±2.160 41.15 
2d 14.9±1.000 52.09 14.2±0.866 49.82 17.2±0.860 60.35 14.6±2.160 46.94 
2e 12.3±1.000 43.00 12.2±0.866 42.80 14.2±0.860 49.82 12.9±2.160 41.48 
2f 18.2±1.000 63.63 17.7±0.866 62.10 16.7±0.860 58.59 18.1±2.160 58.20 
Ofloxacin 28.6±1.890 100 28.5±1.800 100 28.5±1.510 100 31.1±1.500 100 
Data presented in Mean ± SD (N=3), Concentration of derivatives = 25µg/dish, Concentration of Ofloxacin = 25µg/ml 
 
Evaluation of antibacterial Activity 
The compounds were evaluated for antibacterial activity using disc 
diffusion method. A few of the compounds showed moderate activity 
comparing to standard drug. The data is given in the Table-3.  
The results revealed that compounds 1a, 2b and 2f exhibited good 
antibacterial activity and 1b, 1c, 2a, and 2d showed moderate 
antibacterial activity as compared with standard drug Ofloxacin. 
CONCLUSION 
This study provides the simple method for the synthesis of new 
benzenzenesulfonamide based bipyrazoles which plays important 
role in numerous bioactive compounds. The compounds were 
evaluated for antibacterial activity using disc diffusion method. The 
results revealed that compounds 1a, 2b and 2f exhibited good 
antibacterial activity and 1b, 1c, 2a, and 2d showed moderate 
antibacterial activity as compared with standard drug Ofloxacin. 
Singh et al. 
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